AI Article Synopsis
- The study evaluates the pituitary-ovarian axis in girls with exaggerated thelarche, which is early breast development accompanied by signs of increased estrogen effects, without advancing to full puberty.
- It involved comparing hormone levels (FSH, LH, E2) before and after a gonadotropin-releasing hormone agonist (GnRHa) test in three groups of girls: those with exaggerated thelarche, those with premature adrenarche, and those with central precocious puberty.
- Results indicated that girls with exaggerated thelarche had higher peak FSH and E2 levels after GnRHa administration compared to those with adrenarche, suggesting that their estrogen effects are driven mainly by
Article Abstract
Purpose: To assess the dynamics of the pituitary-ovarian axis in exaggerated thelarche, defined as premature thelarche associated with signs of systemic estrogen effects (advanced bone age and/or growth acceleration) without progression to complete puberty.
Subjects And Methods: Seven girls (age < 2.5 years) with exaggerated thelarche, 6 girls with inactive pituitary-ovarian axis (premature adrenarche) and 21 girls with activated axis (central precocious puberty) had serum FSH, LH and E2 measured serially before and 1 to 24 h after gonadotropin-releasing hormone agonist (GnRHa) administration (leuprolide, 20 micrograms/kg sc), used as a test of combined pituitary-ovarian stimulation.
Results: Although girls in the exaggerated thelarche and adrenarche group had similar [mean (SEM)] baseline FSH [3.2 (0.9) vs 1.4 (0.3) IU/l], LH [0.36 (0.1) vs 0.27 (0.02) IU/l] and E2 [20 (1.2) vs 21 (2) pmol/l] concentrations, and similar peak post-GnRHa LH concentrations [5.5 (1.1) vs 2.4 (0.5) IU/l], girls with exaggerated thelarche achieved higher peak FSH [41 (9) vs 14 (3) IU/l, p < 0.01] and E2 [243 (40) vs 37 (6) pmol/l, p < 0.001] concentrations after GnRHa. In comparison to patients with exaggerated thelarche, girls with precocious puberty had higher (p < 0.01-0.001) baseline LH [3.6 (0.8) IU/l], baseline E2 [69(11) pmol/l], GnRHa-stimulated peak LH [68 (17) IU/l] and peak E2 [648 (58) pmol/l] concentrations, but similar FSH parameters.
Conclusions: Girls with exaggerated thelarche exhibit substantial E2 secretory potential that can be demonstrated by GnRHa stimulation, is predominantly FSH-driven, and probably accounts for the manifestations of estrogen effect seen in these girls.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1530/acta.0.1280345 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of early puberty prevalence and time of addition thelarche to pubarche in girls with premature pubarche: two-year follow-up results.
Clin Pediatr Endocrinol
November 2021
Department of Pediatric Endocrinology, School of Medicine, Ankara University, Ankara, Turkey.
We aimed to determine the prevalence of early puberty in girls with premature pubarche and analyze the time interval between their pubarche and succeeding thelarche. This study included 60 female children with premature pubarche. We retrospectively collected clinical, laboratory, and radiological findings from all participants.
View Article and Find Full Text PDFThe Diagnostic Value of Pelvic Ultrasound in Girls with Central Precocious Puberty.
Chonnam Med J
January 2016
Department of Radiology, Inha University School of Medicine, Inha University Hospital, Incheon, Korea.
Article Synopsis
- - The GnRH stimulation test is crucial for distinguishing between central precocious puberty (CPP) and exaggerated thelarche (ET), but has limitations prompting research into other diagnostics like pelvic ultrasound.
- - This study analyzed 192 girls under 8 years old with early puberty signs, revealing 48.4% were diagnosed with CPP, which had a notable increase in uterine volume compared to ET (4.31 mL vs. 3.05 mL).
- - While uterine volume was a predictive factor for CPP, with a threshold of 3.30 mL, the study concluded there were no definitive ultrasound cutoff values, suggesting a combination of ultrasound and other tests for effective CPP diagnosis.
Premature thelarche from phenotype to genotype.
Pediatr Endocrinol Rev
March 2008
Institute of Maternal and Child Research, (IDIMI), School of Medicine, University of Chile, Casilla 226-3, Santiago, Chile.
Premature thelarche is a benign condition, which has been described as a "variant of puberty". Early breast development is especially prevalent during the first year of life, when the gonadal axis is usually active. Ultrasensitive bioassays have described higher estrogen levels in these girls compared to controls.
View Article and Find Full Text PDFActivating GNAS1 gene mutations in patients with premature thelarche.
J Pediatr
August 2004
Institute of Maternal and Child Research, San Borja Arriarán Clinical Hospital, School of Medicine, University of Chile, Santiago, Chile.
Objective: To identify GNAS1 gene mutations in girls with exaggerated and/or chronic fluctuating thelarche for at least 1-year duration with no other signs of precocious puberty, skeletal dysplasia, or typical skin lesions of McCune-Albright syndrome.
Study Design: We studied the GNAS1 gene mutation by allele-specific polymerase chain reaction and enzymatic digestion in leukocyte DNA in 23 girls previously described.
Results: Fluctuating thelarche was present in 14 girls and exaggerated thelarche was observed in 9.
[Thelarche praecox - gray zone of precocious puberty].
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw
November 2003
Premature breast enlargement (premature thelarche) is not uncommon in girls younger than 8 years with the highest incidence below 2 years of age. It is usually a benign non-progressive condition. The pathogenesis of premature thelarche is unknown and controversial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!